Literature DB >> 30057227

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

Matthew T Mefford1, Gabriel S Tajeu2, Rikki M Tanner1, Lisandro D Colantonio1, Keri L Monda3, Ricardo Dent3, Michael E Farkouh4, Robert S Rosenson5, Monika M Safford6, Paul Muntner7.   

Abstract

Guidelines recommend attempting to reinitiate statins in patients who discontinue treatment. Previous experiences while taking a statin, including side effects, may reduce a patient's willingness to reinitiate treatment. We determined the percentage of adults who are willing to reinitiate statin therapy after treatment discontinuation. Factors associated with willingness to reinitiate a statin were also examined. A statin questionnaire was administered and study examination conducted in black and white US adults enrolled in the nationwide REasons for Geographic And Racial Differences in Stroke study from 2013 to 2017. In participants who self-reported ever having taken a statin (n = 7,216, mean age 72 years, 53% women, 34% black), 1,081 (15%) reported having discontinued treatment. Among those who discontinued treatment, statin side effects, perceived lack of need for a statin, and cost were reported by 66%, 31%, and 3% of participants, respectively. Overall, 37% of participants who had discontinued treatment were willing to reinitiate statin therapy. Participants who discontinued treatment due to cost (prevalence ratio [PR] 1.61; 95% confidence interval (CI) 1.01, 2.57) were more likely to report a willingness to reinitiate therapy. Participants with a low-density lipoprotein-cholesterol ≥130 mg/dl versus <100 mg/dl (PR 0.69; 95% CI 0.53, 0. 88) and who discontinued treatment due to side effects (PR 0.51; 95% CI 0.41, 0.64) were less likely to report willingness to reinitiate statin therapy. In conclusion, a substantial proportion of participants who discontinued statin therapy were willing to reinitiate treatment. Healthcare providers should discuss reinitiation of statin therapy with their patients who have discontinued treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30057227      PMCID: PMC9581445          DOI: 10.1016/j.amjcard.2018.05.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   3.133


  28 in total

1.  Primary Care Physician Perspectives on Barriers to Statin Treatment.

Authors:  Rikki M Tanner; Monika M Safford; Keri L Monda; Benjamin Taylor; Ronan O'Beirne; Melanie Morris; Lisandro D Colantonio; Ricardo Dent; Paul Muntner; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

2.  Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation.

Authors:  Katherine J Lee; John B Carlin
Journal:  Am J Epidemiol       Date:  2010-01-27       Impact factor: 4.897

3.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

Authors:  Warner M Mampuya; David Frid; Michael Rocco; Julie Huang; Danielle M Brennan; Stanley L Hazen; Leslie Cho
Journal:  Am Heart J       Date:  2013-08-05       Impact factor: 4.749

4.  Geographic variation in medication adherence in commercial and Medicare part D populations.

Authors:  Joseph E Couto; Janki M Panchal; Lincy S Lal; Thomas J Bunz; Jon E Maesner; Terrence O'Brien; Tanvir Khan
Journal:  J Manag Care Spec Pharm       Date:  2014-08

5.  An assessment by the Statin Intolerance Panel: 2014 update.

Authors:  John R Guyton; Harold E Bays; Scott M Grundy; Terry A Jacobson
Journal:  J Clin Lipidol       Date:  2014 May-Jun       Impact factor: 4.766

6.  Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.

Authors:  James M Backes; Carmelo V Venero; Cheryl A Gibson; Janelle F Ruisinger; Patricia A Howard; Paul D Thompson; Patrick M Moriarty
Journal:  Ann Pharmacother       Date:  2008-02-19       Impact factor: 3.154

7.  Factors related to adherence to statin therapy.

Authors:  Brandy McGinnis; Kari L Olson; David Magid; Elizabeth Bayliss; Eli J Korner; David W Brand; John F Steiner
Journal:  Ann Pharmacother       Date:  2007-10-09       Impact factor: 3.154

Review 8.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Authors:  Sarah Lewington; Gary Whitlock; Robert Clarke; Paul Sherliker; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

9.  Physician communication and patient adherence to treatment: a meta-analysis.

Authors:  Kelly B Haskard Zolnierek; M Robin Dimatteo
Journal:  Med Care       Date:  2009-08       Impact factor: 2.983

10.  Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study.

Authors:  L Wei; J Wang; P Thompson; S Wong; A D Struthers; T M MacDonald
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

View more
  3 in total

1.  Neighborhood Participation Is Less Likely among Older Adults with Sidewalk Problems.

Authors:  Erica Twardzik; Philippa Clarke; Suzanne Judd; Natalie Colabianchi
Journal:  J Aging Health       Date:  2020-09-22

2.  Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis.

Authors:  Min Yan Shi; In Hyuk Bang; Chang Yeob Han; Dae Ho Lee; Byung-Hyun Park; Eun Ju Bae
Journal:  Theranostics       Date:  2020-09-15       Impact factor: 11.556

3.  Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation.

Authors:  Elizabeth A Jackson; Kristine Ruppert; Carol A Derby; Yinjuan Lian; Claudia U Chae; Rasa Kazlauskaite; Genevieve Neal-Perry; Samar R El Khoudary; Siobán D Harlow; Daniel H Solomon
Journal:  Clin Cardiol       Date:  2020-08-30       Impact factor: 2.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.